When the world shut down, Roche went all-in and carried on its research programs

It was no easy decision to keep clinical trials going last spring, when the Covid-19 pandemic escalated, but Roche quickly decided that it would keep as much research going as it could, says research executive. This is now paying off.
Roche SVP, Global Head Oncology, Pharma Research and Early Development Dominik Ruettinger. | Photo: Roche / PR
Roche SVP, Global Head Oncology, Pharma Research and Early Development Dominik Ruettinger. | Photo: Roche / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Even though pharmaceutical companies, overall, have not been hit as hard by the Covid-19 pandemic as most other industries, pharmaceutical and biotech companies have been especially challenged in one particular area, which is that of clinical research.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading